ES2882115T3 - Nuevo uso de sulfato de dextrano - Google Patents
Nuevo uso de sulfato de dextrano Download PDFInfo
- Publication number
- ES2882115T3 ES2882115T3 ES16830923T ES16830923T ES2882115T3 ES 2882115 T3 ES2882115 T3 ES 2882115T3 ES 16830923 T ES16830923 T ES 16830923T ES 16830923 T ES16830923 T ES 16830923T ES 2882115 T3 ES2882115 T3 ES 2882115T3
- Authority
- ES
- Spain
- Prior art keywords
- dextran sulfate
- pharmaceutically acceptable
- acceptable salt
- injection
- fibrosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960000633 dextran sulfate Drugs 0.000 title claims abstract description 116
- 150000003839 salts Chemical class 0.000 claims abstract description 51
- 238000007910 systemic administration Methods 0.000 claims abstract description 23
- 208000010125 myocardial infarction Diseases 0.000 claims abstract description 19
- 230000009787 cardiac fibrosis Effects 0.000 claims abstract description 18
- 239000007864 aqueous solution Substances 0.000 claims abstract description 16
- 238000002347 injection Methods 0.000 claims abstract description 16
- 239000007924 injection Substances 0.000 claims abstract description 16
- 238000011282 treatment Methods 0.000 claims abstract description 13
- 230000005764 inhibitory process Effects 0.000 claims abstract description 6
- 238000010253 intravenous injection Methods 0.000 claims abstract description 6
- 238000010254 subcutaneous injection Methods 0.000 claims abstract description 6
- 239000007929 subcutaneous injection Substances 0.000 claims abstract description 6
- 230000002265 prevention Effects 0.000 claims abstract description 5
- 239000003125 aqueous solvent Substances 0.000 claims abstract description 4
- 208000031225 myocardial ischemia Diseases 0.000 claims abstract description 4
- 206010016654 Fibrosis Diseases 0.000 claims description 61
- 230000004761 fibrosis Effects 0.000 claims description 61
- 210000002216 heart Anatomy 0.000 claims description 17
- 230000037396 body weight Effects 0.000 claims description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 8
- 239000011593 sulfur Substances 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 6
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 238000004611 spectroscopical analysis Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 210000005003 heart tissue Anatomy 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 206010061216 Infarction Diseases 0.000 description 7
- 230000000254 damaging effect Effects 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 230000007574 infarction Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- 210000002808 connective tissue Anatomy 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000003176 fibrotic effect Effects 0.000 description 5
- 230000000302 ischemic effect Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229960002303 citric acid monohydrate Drugs 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 206010019280 Heart failures Diseases 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000002939 deleterious effect Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 230000001627 detrimental effect Effects 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000000266 injurious effect Effects 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 206010038748 Restrictive cardiomyopathy Diseases 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229920006318 anionic polymer Polymers 0.000 description 2
- 230000002300 anti-fibrosis Effects 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 230000001746 atrial effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 201000010048 endomyocardial fibrosis Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002270 exclusion chromatography Methods 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000036573 scar formation Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- RQPKNXVVIBYOBX-KDBLBPRBSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-2-(dihydroxyamino)-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.ON(O)[C@H](C(O)=O)CC1=CC=CC=C1 RQPKNXVVIBYOBX-KDBLBPRBSA-N 0.000 description 1
- -1 0.9% NaCl saline Chemical compound 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010072877 Intestinal fibrosis Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007331 pathological accumulation Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/721—Dextrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/02—Dextran; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1551050A SE539575C2 (en) | 2015-07-30 | 2015-07-30 | Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis |
| PCT/SE2016/050720 WO2017018922A1 (en) | 2015-07-30 | 2016-07-15 | New use of dextran sulfate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2882115T3 true ES2882115T3 (es) | 2021-12-01 |
Family
ID=57884849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16830923T Active ES2882115T3 (es) | 2015-07-30 | 2016-07-15 | Nuevo uso de sulfato de dextrano |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10478451B2 (enExample) |
| EP (1) | EP3328395B1 (enExample) |
| JP (1) | JP6837679B2 (enExample) |
| CN (2) | CN114712385A (enExample) |
| BR (1) | BR112018001942A2 (enExample) |
| DK (1) | DK3328395T3 (enExample) |
| EA (1) | EA034313B1 (enExample) |
| ES (1) | ES2882115T3 (enExample) |
| HK (1) | HK1246640A1 (enExample) |
| SE (1) | SE539575C2 (enExample) |
| WO (1) | WO2017018922A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2777836T3 (es) * | 2017-05-17 | 2020-08-06 | Tx Medic Ab | Tratamiento del glaucoma |
| WO2018212708A1 (en) * | 2017-05-17 | 2018-11-22 | Tx Medic Ab | Treatment of glaucoma |
| IL272935B2 (en) * | 2017-09-08 | 2025-04-01 | Tx Medic Ab | New use of dextran sulfate |
| CA3093027A1 (en) * | 2018-03-09 | 2019-09-12 | Carmeda Ab | Improvements to processes for immobilising biological entities |
| SE543275C2 (en) * | 2019-03-07 | 2020-11-10 | Tx Medic Ab | Treatment efficiency evaluation |
| SE544447C2 (en) * | 2020-09-29 | 2022-05-31 | Tx Medic Ab | Treatment of fatty liver diseases |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5605938A (en) * | 1991-05-31 | 1997-02-25 | Gliatech, Inc. | Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate |
| EP0868191A1 (en) | 1995-12-18 | 1998-10-07 | Stichting Sanquin Bloedvoorziening | Potentiation of complement and coagulation inhibitory properties of c1-inhibitor. |
| US20040224922A1 (en) | 1999-08-26 | 2004-11-11 | Malcolm King | Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto |
| SE525461C3 (sv) * | 2002-11-28 | 2005-03-23 | Prophymed Ab | Ny användning av dextransulfat |
| WO2007028053A2 (en) * | 2005-09-02 | 2007-03-08 | X-Cell Medical Incorporated | Methods of treating and preventing cardiac disorders |
| WO2007075388A2 (en) * | 2005-12-15 | 2007-07-05 | X-Cell Medical Incorporated | Methods of locally treating and preventing cardiac disorders |
| CA2685208C (en) * | 2007-04-24 | 2014-04-08 | Novelmed Therapeutics, Inc. | Methods and compositions of inhibiting complement and cellular activation with dextran sulfate |
| WO2011091167A2 (en) * | 2010-01-22 | 2011-07-28 | The General Hospital Corporation | Lysophosphatidic acid receptor targeting for scleroderma and other fibrotic diseases |
| US9393289B2 (en) * | 2011-10-18 | 2016-07-19 | Csl Behring Gmbh | Use of sulfated glycosaminoglycans for improving the bioavailability of factor VIII |
| CN102973593A (zh) * | 2012-11-26 | 2013-03-20 | 合肥博太医药生物技术发展有限公司 | 硫酸葡聚糖在制备治疗肝纤维化药物中的应用 |
| WO2015190989A1 (en) * | 2014-06-12 | 2015-12-17 | Tx Medic Ab | The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject |
| PT3154551T (pt) * | 2014-06-12 | 2019-01-18 | Tx Medic Ab | A utilização de sulfato de dextrano tendo uma massa molecular média inferior a 10000 da para induzir angiogénese num sujeito |
-
2015
- 2015-07-30 SE SE1551050A patent/SE539575C2/en unknown
-
2016
- 2016-07-15 BR BR112018001942A patent/BR112018001942A2/pt not_active Application Discontinuation
- 2016-07-15 WO PCT/SE2016/050720 patent/WO2017018922A1/en not_active Ceased
- 2016-07-15 ES ES16830923T patent/ES2882115T3/es active Active
- 2016-07-15 HK HK18106000.5A patent/HK1246640A1/zh unknown
- 2016-07-15 CN CN202210555037.5A patent/CN114712385A/zh active Pending
- 2016-07-15 CN CN201680044788.3A patent/CN107921055A/zh active Pending
- 2016-07-15 US US15/748,519 patent/US10478451B2/en active Active
- 2016-07-15 DK DK16830923.5T patent/DK3328395T3/da active
- 2016-07-15 JP JP2018503496A patent/JP6837679B2/ja active Active
- 2016-07-15 EA EA201890212A patent/EA034313B1/ru not_active IP Right Cessation
- 2016-07-15 EP EP16830923.5A patent/EP3328395B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6837679B2 (ja) | 2021-03-03 |
| JP2018521086A (ja) | 2018-08-02 |
| EP3328395A4 (en) | 2018-06-20 |
| BR112018001942A2 (pt) | 2018-09-18 |
| US10478451B2 (en) | 2019-11-19 |
| CN107921055A (zh) | 2018-04-17 |
| US20180221403A1 (en) | 2018-08-09 |
| HK1246640A1 (zh) | 2018-09-14 |
| EP3328395A1 (en) | 2018-06-06 |
| CN114712385A (zh) | 2022-07-08 |
| SE1551050A1 (en) | 2017-01-31 |
| EA201890212A1 (ru) | 2018-06-29 |
| EP3328395B1 (en) | 2021-06-09 |
| EA034313B1 (ru) | 2020-01-28 |
| WO2017018922A1 (en) | 2017-02-02 |
| DK3328395T3 (da) | 2021-08-09 |
| SE539575C2 (en) | 2017-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5094799B2 (ja) | 粘膜適用剤及びその製造方法 | |
| ES2957291T3 (es) | Hidrogel de ECM para el tratamiento de la inflamación esofágica | |
| US10478451B2 (en) | Use of dextran sulfate | |
| ES2703785T3 (es) | Método y composición para tratar una enfermedad inflamatoria intestinal sin colectomía | |
| BR112015013711B1 (pt) | membranas em hidrogel para prevenção de aderência | |
| JP6837835B2 (ja) | トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療 | |
| JPWO2013133413A1 (ja) | 粘膜隆起剤 | |
| Tang et al. | Sequential delivery of anti-inflammatory and anti-scar drugs by Rg3 liposome-embedded thiolated chitosan hydrogel eye drops for corneal alkali burn | |
| ES2705069T3 (es) | Uso de sulfato de dextrano que tiene un peso molecular promedio inferior a 10000 da para inducir angiogénesis en un sujeto | |
| ES2659437T3 (es) | Agente para tratar las cicatrices y el envejecimiento de la piel | |
| CN109996553A (zh) | 用于在内窥镜剥离术后预防食管狭窄的自组装肽基质 | |
| US20210145850A1 (en) | Composition, for osteoarthritis treatment, comprising hydrophilized sulfasalazine and hyaluronic acid and method for preparing same | |
| CN101933897B (zh) | 注射用重组人血管内皮抑制素温度敏感性凝胶组合物 | |
| WO2015190989A1 (en) | The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject | |
| JP2010521215A (ja) | 組織の修復を促進する方法 | |
| ES2868134T3 (es) | Composición médica y cosmética biodegradable reabsorbible | |
| CN101229366A (zh) | 成纤维细胞生长因子在制备促进血管生成药物中的应用 | |
| ES3051234T3 (en) | Anti-adhesive hydrogel composition | |
| WO2007046540A1 (ja) | 象牙質－歯髄複合体再生治療剤 | |
| BR102021019418A2 (pt) | Método de tratamento ou prevenção da formação de hérnia | |
| BR112019025223B1 (pt) | Composição médica e cosmética biodegradável reabsorvível compreendendo poli(carbonato de 1,3-trimetileno) |